



KINEXUS

Kinexus Bioinformatics Corporation Appoints Mr. Stephen Kimoff as the Director of Corporate Relations

New Director hired to Assist Kinexus in its Strive for Excellence

PRESS RELEASE - 2000 AUGUST 1

FOR IMMEDIATE RELEASE AUGUST 1, 2000

VANCOUVER, British Columbia - Dr. Steven Pelech, President and C.E.O. of Kinexus Bioinformatics Corporation, is pleased to announce the recent appointment of Mr. Stephen Kimoff as Director of Corporate Relations.

Mr. Kimoff has over twelve years experience in strategic planning and marketing with an emphasis on early stage technology and University R&D spin-off companies in North America. His experience includes four years as the Director of Growth for Univ Tec Inc. and six years as the Senior Project Manager for UBC Real Estate Corporation and Discovery Parks Inc. Mr. Kimoff received his B.Sc. in Geological Sciences and Engineering from the University of British Columbia and completed Canadian Securities and UBC Real Estate Licensing Courses.

Kinexus is a private Vancouver-based company synergizing the powers of genomics, proteomics, Bioinformatics, and the Internet to advance global biomedical research, disease diagnosis and drug discovery. It is a biotechnology/information technology company striving to emerge as a world-leader in providing knowledge about intracellular communication systems that involve protein kinases. Defective cell signalling through these enzymes has been linked to hundreds of diseases in humans. Kinexus plans to deduce the composition and architecture of kinase networks and apply this knowledge for human health and welfare with diversified partners and clients. Initially, the Company will provide cost effective screening services to track the presence and regulation of hundreds of different kinases and their targets in cell and tissue specimens provided by clients from academia and industry. Kinexus will further develop and market proprietary kinase-focused databases by annotating complex cell signalling pathways, modeling disease states in signal transduction pathways, identifying drug-pathway interactions and by 3D molecular modeling of kinases for rational design of drug candidates. Kinexus is strategically positioned to take full advantage of the success of the human genome project to improve human health.

For further information, please contact Kinexus Bioinformatics Corporation toll free at 1-866-KINEXUS or visit our website at www.kinexus.ca.